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Objective: Dementia with Lewy Bodies (DLB) is the second most common type of
neurodegenerative dementia. Yet, the domain-specific cognitive impairment of the mild
cognitive impairment (MCI) phase of this disease (DLB-MCI) is still not been established.
This article gives an updated review on the neuropsychological profile of DLB-MCI,
building on the findings from a previous review.
Methods: We performed systematic review and searched five different electronic
databases (Scopus, Cochrane, EMBASE, MEDLINE, and PsycINFO) in May 2020 based
on a PICO scheme. Our search was then restricted to articles published in 2019 and
2020. Ending up with a total of 90 articles to be reviewed by abstract and/or full text.
Results: In total four papers were included, whereof only one met our full inclusion
criteria. Despite a substantial heterogeneity, our findings indicate that DLB-MCI patients
have a pattern of executive, visuospatial, and attentional deficits.
Conclusion: The findings indicate that the neuropsychological profile of DLB-MCI
is characterized by executive, visuospatial, and attentional deficits. Furthermore, the
shortage of studies clearly underlines the paucity of published research into DLB-MCI
and emphasizes the need for well-controlled studies.
Keywords: dementia with lewy bodies (DLB), mild cognitive impaiment, cognition, predementia,
neuropsychological profiles, prodromal DLB
INTRODUCTION
Dementia with Lewy bodies (DLB) comprises up to 24% of all neurodegenerative dementia cases
(Hogan et al., 2016). It is thereby the second most prevalent type of neurodegenerative dementia,
only exceeded by Alzheimer’s Disease (AD), and the need for accurate and early diagnostic
identification is thus of great social importance. DLB is characterized by dementia in combination
with different core clinical features of rapid eye movement (REM) behavior disorder (RBD),
parkinsonism, cognitive and alertness fluctuations, and visual hallucinations. In addition, there are
a number of supportive clinical features, indicative biomarkers, and supportive biomarkers to be
used when establishing a clinical diagnosis (McKeith et al., 2017).
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Both Parkinson’s disease (PD) with and without dementia
(PDD) and DLB are thought to be on separate ends of a
continuum of Lewy Body diseases (LBDs) (Aarsland et al., 2009).
Thus, the two diagnoses share important pathophysiological and
clinical features, including motor, neuropsychiatric, cognitive,
and autonomic symptoms. Because of this extensive overlap, it
has even been up for discussion whether PDD and DLB really are
two distinct diagnoses (McKeith, 2009; Berg et al., 2014). Today
DLB is diagnosed when dementia precedes or accompanies
parkinsonism, whereas PDD is diagnosed when dementia occurs
after PD onset. For research matters, the differentiation of DLB
and PDD is defined by a 1-year criterion, where PDD is diagnosed
when PD occurs a year or more before dementia (McKeith et al.,
2017).
Moreover, studies also suggest that both neuropsychological
deficits and core clinical features arises early in the disease
progression (Sperling et al., 2011; Donaghy et al., 2015), and the
phase preceding dementia has therefore been heavily investigated
over the last years. This phase, called the mild cognitive
impairment (MCI) stage, points to the intermediate stage
between normal cognitive aging and dementia. Here objective
cognitive decline is present, but not to the extent that it interferes
with functional daily living. Research now suggests that the MCI
stage due to the different dementia types have their unique
cognitive profiles equal to their associated dementias. As of today,
the MCI stage for both AD (AD-MCI) and PDD (PD-MCI) are
defined (Albert et al., 2011; Litvan et al., 2012), but the proposed
MCI stage for DLB (DLB-MCI) (Donaghy et al., 2018) is still
lacking support from clinical studies. Indeed, research criteria
for the diagnosis of prodromal DLB has only recently been
published (McKeith et al., 2020), defining DLB-MCI as MCI with
concurrent probable or possible DLB (McKeith et al., 2017, 2020).
Furthermore, the need for validation of the DLB-MCI criteria
is especially pressing, as there is an overall trend in the field of
dementia to advance the point of diagnosis to the MCI stage.
The high rate of misdiagnosis, the symptomatic overlap between
different diagnoses, and the fact that the different diagnoses calls
for different treatment makes the validation even more exigent.
Moreover, defining the cognitive profile of DLB-MCI might also
be of important prognostic value, as neuropsychological tests is
shown to be good predictors for conversion from MCI to AD
(Belleville et al., 2017).
A recent review indicates that the cognitive profile of DLB-
MCI is characterized by executive dysfunction, slow processing
speed, in addition to visuospatial and working memory deficits
(Ciafone et al., 2020). It thus resembles the cognitive profile for
the PD-MCI. However, the authors emphasized the paucity of
research into DLB-MCI and therefore the need for more studies.
Given both the time passed since Donaghy et al. (2018) proposed
a DLB-MCI and the importance of the area, one might expect
that more research is now available.
METHODS
This is an updated and systematic review of the evidence base
underlying the domain-specific cognitive impairment associated
with DLB-MCI, building on a recently published review based on
a search performed in January 2019 (Ciafone et al., 2020). This
systematic review conforms to the PRISMA reporting guidelines.
Search Strategy
Building on a PICO scheme (Supplementary Material),
we searched Scopus, Cochrane, EMBASE, MEDLINE, and
PsycINFO databases in May 2020 (2020-05-14 and 2020-05-22).
Free text words were used in all databases: “Lewy” or “DLB” with
“dementia” in combination with “prodromal∗” and “cognit∗
dysfunction/decline/impair∗/defect∗/deficit∗,” MCI and/or
SCD [subjective cognitive decline]. In addition to text words,
medical subject headings from thesaurus were used when
possible, thus in Medline and Cochrane Central (Lewy Body
disease, prodromal symptoms, cognitive dysfunction), EMBASE
(prodromal symptoms, diffuse Lewy body disease, dementia
assessment, cognitive defect), and PsycINFO (dementia with
Lewy bodies, prodrome, cognitive impairment). The search
was restricted to title, abstract, and keyword. The search was
performed in collaboration with a University librarian.
Inclusion and Exclusion Criteria
We included studies that measured domain specific cognitive
functioning in DLB-MCI. Both studies that reported scores
on isolated neuropsychological tests as well as those including
domain specific composite scores were accepted. On the other
hand, our exclusion criteria were n < 10, lack of healthy
control (HC) subjects, unclear diagnostic and MCI definitions,
and use of global cognitive composite scores. That is, studies
who only reported cognition in terms of global Mini-Mental
Status Examination (MMSE) or Montreal Cognitive Assessment
(MoCA) (Nasreddine et al., 2005) scores were excluded, as
opposed to those who for example reported domain-specific
MoCA subscores. Furthermore, studies including only one case
of DLB-MCI in addition to other MCI groups were considered
case studies, and thus removed.
RESULTS
The search yielded a total of 10,276 references: 6,300 after
removing duplicates using EndNote and 5,747 after manually
removing remaining duplicates. These references were further
restricted to those published in 2019 and 2020, resulting in a
total of 684 references subjected for title screening. After a gross
title screen, removing animal studies, articles with a flagrantly
irrelevant topic or articles that were not published in English
journals, 89 references remained to be reviewed by abstract.
See Figure 1.
The abstract review typically removed case studies, and
articles that did not target DLB did not include cognitive
measures or only included global cognitive composite scores
(such as MMSE or MoCA total score). The main reasons
for removal after full text revision were studies that did not
distinguish between prodromal symptoms and symptoms of
(mild) dementia, unclear neuropsychological data, and lack
of control groups. Reviews, meta-analyses, abstracts, posters,
discussion papers, and commentaries were also screened out
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FIGURE 1 | PRISMA flow diagram. Overview of search and extraction process. From: Moher et al. (2009). For more information, visit www.prisma-statement.org.
during the process. At both the point of abstract review and
full text review, ambiguous cases were discussed between the
main authors (MSH, MHB) until consensus was achieved.
We extracted baseline data in longitudinal studies, unless
otherwise stated.
Since only one study met the full inclusion criteria (Massa
et al., 2019), we post hoc chose to include studies that did not have
HCs and had unclear diagnostic criteria. Doing this we ended up
with a total of four articles for this review (Massa et al., 2019;
Unger et al., 2019; van de Beek et al., 2020; Yoo et al., 2020).
See Table 1.
Synthetisized Findings
The only study that met the full inclusion criteria was a
longitudinal study by Massa et al. (2019). The DLB-MCI patients
were diagnosed with MCI prior to PD, with a mean time
of 2.9 ± 1.9 years (range 0.5–6.1). These patients were then
matched and compared to both HCs and cognitively normal
PD patients. However, they only used cognitively normal PD
patients instead of HCs in the analysis of cognitive data.
They report heterogeneous findings at the baseline, with the
cognitive profiles of DLB-MCI both being amnestic, non-
amnestic and single- or multidomain. They did nevertheless find































TABLE 1 | Overview of the included studies.
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The Clock Drawing test and the TMT-B to be the most impaired
cognitive tests in DLB-MCI. Compared to cognitively normal
PD patients, the DLB-MCI patients had significantly reduced
scores on tests measuring executive, attentional, visuospatial,
and memory function. They found one test of visuospatial
working memory and one of semantic verbal fluency to be
able to fully separate those who develop LBD dementia from
those who do not. The authors concluded that a worse
visuospatial working memory and semantic verbal fluency
is among factors putting a patient at higher risk of LBD
dementia development.
Combining this with the neuroimaging findings, the authors
conclude that patients with cognitive complaints and PD is best
characterized as prodromal LBD (Donaghy and McKeith, 2014;
McKeith et al., 2016) at first presentation, due to the extensive
pathophysiological overlap.
The last three included studies did not, for various reasons,
meet our full inclusion criteria. van de Beek et al. (2020) did not
include HCs, Unger et al. (2019) lacked both HCs and had an
unclear MCI definition, and lastly Yoo et al. (2020) both had an
unclear MCI definition and a combined PD/DLB-MCI group.
Despite this, summed findings do point to DLB-MCI patients
having poorer executive and visuospatial function compared to
AD-MCI patients (van de Beek et al., 2020) and poorer executive
and attentional functioning compared to HCs (Yoo et al., 2020).
Moreover, a deterioration in attentional (Unger et al., 2019;
van de Beek et al., 2020) and visuospatial/executive function
(Unger et al., 2019) has been reported for DLB-MCI patients
converting to dementia. Interestingly, van de Beek et al. (2020)
also found that a poorer attentional function at first visit was
associated with faster progression to dementia. The authors then
concluded that this probably is an effect of these patients being
closer to dementia, as DLB is characterized with more prominent
attentional dysfunction early on in the disease course. Hence,
the results point to a pattern of executive, visuospatial, and
attentional deficits for persons living with DLB-MCI. Even so, the
few existing studies provide rather heterogeneous findings, which
is in line with Ciafone et al. (2020)’s findings.
When it comes to memory, the results are somewhat more
mixed. While some of the studies find memory to be spared
compared to AD-MCI (van de Beek et al., 2020), others find
memory to be affected in DLB-MCI compared to HCs (Yoo
et al., 2020). Lastly, both van de Beek et al. (2020) and Unger
et al. (2019) report memory deterioration to be associated with
conversion to dementia.
DISCUSSION
Despite being already 2 years since Donaghy et al. (2018)
proposed criteria for DLB-MCI, only one study met the full
inclusion criteria for this review (Massa et al., 2019). Further,
only one study focused primarily on cognition (van de Beek
et al., 2020), while the others had either color vision impairments
or neuroimaging as their main focus. This shortage clearly
underlines the paucity of research into DLB-MCI and emphasizes
the need for well-controlled studies. Thus, the situation seems
to be quite similar to that of January 2019 (Ciafone et al.,
2020), and the cognition of DLB-MCI is still a scarce field of
research. However, there are well-designed ongoing studies, that
is, the Dementia Disease Initiation (DDI)-study (Fladby et al.,
2017), that focuses on prodromal dementia symptoms, including
prodromal DLB symptoms.
Because the main part of the included studies did not meet
our full inclusion criteria, it is timely to question their utility for
the scope of this review. Either way, the findings do however
push toward a neuropsychological profile characterized by
visuospatial, executive, and attentional deficits. In fact, this is in
line with what we also found in mild DLB (Brønnick et al., 2016).
Furthermore, Massa et al. (2019) also found a worse
visuospatial working memory and semantic verbal fluency to
be a risk factor for LBD dementia development. One might
question the specificity of this finding because it is in line
with what is also found to be the case for conversion from
MCI to AD (Belleville et al., 2017). Moreover, the results are
inconclusive when it comes to the memory function of DLB-MCI
patients. One might theorize that the large heterogeneity is due
to some patients having a mixed DLB-AD pathology. However,
caregivers to patients with DLB report memory impairment
to be the most common symptom for both DLB and AD
(Auning et al., 2011).
In addition, the substantial heterogeneity in the reported
findings may firstly be due to the considerable variation in
applied methods and definitions. One of the included studies
used domain specific screening tools (Unger et al., 2019),
while the others used more exhaustive neuropsychological tests.
Further, some used composite scores (van de Beek et al., 2020;
Yoo et al., 2020), while other analyzed isolated test scores (Massa
et al., 2019; Unger et al., 2019). Moreover, some of the studies
used standardized scores in the analyses (van de Beek et al.,
2020; Yoo et al., 2020), while others used raw scores (Massa
et al., 2019; Unger et al., 2019). This is somewhat problematic,
due to age, sex, and educational differences between the subjects,
as well as substantial differences in the normative basis for the
different tests.
Second, we do not know whether all of the patients
diagnosed as prodromal DLB did actually develop DLB. Only
two of the included studies were longitudinal (Massa et al.,
2019; van de Beek et al., 2020), and in these studies just
about half of the subjects diagnosed as DLB-MCI actually
developed dementia. In addition, in van de Beek et al. (2020),
patients who received a probable DLB diagnosis at some
point during follow-up were retrospectively defined as DLB-
MCI (44%). Hence, these subjects probably did not reach
the same criteria for a clinical diagnosis DLB-MCI at first
presentation as the other ones, and grouping these together
is thus problematic with respect to operationalization. The
ideal situation would be to have a group of patients clinically
diagnosed with DLB-MCI who later on received a definite
DLB diagnosis.
Third, the heterogeneity of the findings may also be a natural
cause of the varying terms and diagnostic criteria used in the
different studies. Indeed, only van de Beek et al. (2020) stated a
clear MCI definition together with McKeith et al. (2017) criteria
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for probable DLB. The other studies chunked PDD and DLB
together to an LBD-MCI group, or had a restricted focus on
parkinsonism or RBD, not taking the other DLB core criteria
into account. For example, Massa et al. (2019) did not use the
1-year rule as is stated for research purposes to differentiate
between PDD and DLB. Furthermore, Yoo et al. (2020) also
chunked PDD andDLB together in an LBD-MCI group, of which
only four of them were diagnosed as DLB-MCI, as opposed to
14 as PD-MCI. This bias clearly affects the utility of this study
as a DLB-MCI study; in fact, it may be more representable
as a PD-MCI study.
Future studies must therefore apply the newly published
consensus criteria (McKeith et al., 2020) to make comparison
between studies possible. Here MCI is defined as a cognitive
concern proposed by the patient, an informant, or a clinician,
in addition to objective impairment in one or more cognitive
domains and preserved ADL. In order to receive a diagnosis of
DLB-MCI, the patients must also meet the criteria for probable
or possible DLB (McKeith et al., 2017, 2020). In the time ahead,
we accordingly expect a substantial amount of studies using these
new criteria. Despite the budding amount of research suggesting
visuospatial, attentional, and executive deficits in DLB-MCI, a
sound conclusion regarding the cognitive profile of DLB-MCI
awaits a future body of research using the McKeith et al. (2020)
criteria. Additionally, studies with higher focus on new potential
biomarkers and a larger number of included subjects is important
to further subgroup this heterogeneous group and to get more
robust and representative findings.
Lastly, some of the included studies proposed that a DLB-
MCI diagnosis might not be fruitful, due to a both substantial
symptomatic heterogeneity and overlap (Massa et al., 2019; van
de Beek et al., 2020). At this point, however, it seems like a rather
premature proposition due to the lack of well-controlled studies.
As mentioned, Massa et al. (2019) suggests a prodromal LBD
diagnosis for patients with both PD and cognitive complaints,
due to their finding of a substantial pathophysiological overlap
between PD-MCI and DLB-MCI patients. This may, however, be
a spurious effect because they did not adhere to the 1-year rule
and chunked prodromal PDD and DLB patients together in their
prodromal LBD group. Hence, a pathophysiological overlap is as
expected. Nonetheless, this discourse points to the necessity of
conducting proper neuropsychological assessments of all patients
with PD.
Study Limitations and Strengths
The strength of this study is the thorough and systematic
search in which it is based on, thus making it unlikely that
we missed relevant studies. Our study does, however, have
some limitations, with the most obvious being the few studies
included. All of the studies also had few study subjects included.
One can therefore not use the findings from this study to
validate the neuropsychological profile of DLB-MCI. Another
minor limitation is that we are building on a recently published
review without knowing the exact search strategy of this study.
Moreover, our searches were not performed in the exact same
databases as Ciafone et al. (2020).
CONCLUSION
As Ciafone et al. (2020), our findings indicate that DLB-MCI
patients have a pattern of executive, visuospatial, and attentional
deficits. Hence, it resembles that of DLB. However, there is a clear
lack of well-controlled studies with a sizable number of study
subjects focusing on cognition in DLB-MCI. One major reason
for this might be the challenge of identifying these patients due
to both heterogeneous symptom presentation in the prodromal
stage and the lack of clear definition. With recently published
research criteria for DLB-MCI (McKeith et al., 2020), it might
be easier to identify these patients, and a wealth of studies is
therefore expected to come in the near future.
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